DK3298036T3 - Fremgangsmåder til forberedelse af modificeret von Willebrand faktor - Google Patents
Fremgangsmåder til forberedelse af modificeret von Willebrand faktor Download PDFInfo
- Publication number
- DK3298036T3 DK3298036T3 DK16725477.0T DK16725477T DK3298036T3 DK 3298036 T3 DK3298036 T3 DK 3298036T3 DK 16725477 T DK16725477 T DK 16725477T DK 3298036 T3 DK3298036 T3 DK 3298036T3
- Authority
- DK
- Denmark
- Prior art keywords
- methods
- von willebrand
- willebrand factor
- preparing modified
- modified von
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1741—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals alpha-Glycoproteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/473—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used alpha-Glycoproteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/96—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation using ion-exchange
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Marine Sciences & Fisheries (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15168934 | 2015-05-22 | ||
| PCT/EP2016/061440 WO2016188905A1 (en) | 2015-05-22 | 2016-05-20 | Methods for preparing modified von willebrand factor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3298036T3 true DK3298036T3 (da) | 2022-06-07 |
Family
ID=53191564
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16725477.0T DK3298036T3 (da) | 2015-05-22 | 2016-05-20 | Fremgangsmåder til forberedelse af modificeret von Willebrand faktor |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US10772936B2 (da) |
| EP (2) | EP3298036B1 (da) |
| JP (1) | JP6651548B2 (da) |
| KR (1) | KR20180012303A (da) |
| CN (1) | CN107810194B (da) |
| AU (1) | AU2016267539B2 (da) |
| BR (1) | BR112017024714A2 (da) |
| CA (1) | CA2986625A1 (da) |
| DK (1) | DK3298036T3 (da) |
| ES (1) | ES2912300T3 (da) |
| IL (1) | IL255711A (da) |
| MX (1) | MX2017014872A (da) |
| RU (1) | RU2017145002A (da) |
| SG (2) | SG11201708754XA (da) |
| TW (1) | TW201713686A (da) |
| WO (1) | WO2016188905A1 (da) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201912768YA (en) | 2016-11-11 | 2020-02-27 | CSL Behring Lengnau AG | Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder |
| JP7252890B2 (ja) | 2016-11-11 | 2023-04-05 | ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト | 血友病を処置するための切断型フォン・ヴィルブランド因子ポリペプチド |
| ES2966835T3 (es) | 2017-06-22 | 2024-04-24 | CSL Behring Lengnau AG | Modulación de la inmunogenicidad del FVIII por VWF truncado |
| JP7780341B2 (ja) * | 2019-07-04 | 2025-12-04 | ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト | 第ＶＩＩＩ凝固因子のｉｎ ｖｉｔｒｏでの安定性を向上させるための切断型フォン・ヴィレブランド因子（ＶＷＦ） |
| JP7803014B2 (ja) * | 2019-09-30 | 2026-01-21 | バイオベラティブ セラピューティクス インコーポレイテッド | レンチウイルスベクター製剤 |
| WO2026009803A1 (ja) * | 2024-07-05 | 2026-01-08 | 国立大学法人九州大学 | ヘパリン様物質を製造する方法 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| AU2353384A (en) | 1983-01-19 | 1984-07-26 | Genentech Inc. | Amplification in eukaryotic host cells |
| US4713339A (en) | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
| US4970300A (en) | 1985-02-01 | 1990-11-13 | New York University | Modified factor VIII |
| AU6029594A (en) | 1993-01-15 | 1994-08-15 | Enzon, Inc. | Factor viii - polymeric conjugates |
| JPH11501506A (ja) | 1994-12-12 | 1999-02-09 | ベス イスラエル デアコネス メディカル センター | キメラ型サイトカインおよびその利用 |
| WO1997003193A1 (en) | 1995-07-11 | 1997-01-30 | Chiron Corporation | Novel factor viii:c polypeptide analogs with altered metal-binding properties |
| SE9503380D0 (sv) | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
| US20040092442A1 (en) | 1996-04-24 | 2004-05-13 | University Of Michigan | Inactivation resistant factor VIII |
| ATE502958T1 (de) | 1996-04-24 | 2011-04-15 | Univ Michigan | Gegen inaktivierung resistenter faktor viii |
| DK1015622T3 (da) | 1997-01-16 | 2004-08-02 | Neose Technologies Inc | Praktisk sialylering in vitro af rekombinante glycoproteiner |
| AU747391B2 (en) | 1998-04-27 | 2002-05-16 | Cantab Biopharmaceuticals Patents Limited | Pharmaceutical composition comprising factor VIII and neutral liposomes |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| US6887470B1 (en) | 1999-09-10 | 2005-05-03 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
| EP1351986A2 (en) | 2001-01-12 | 2003-10-15 | The American National Red Cross | Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor viii |
| JP4361786B2 (ja) | 2001-06-14 | 2009-11-11 | ザ スクリプス リサーチ インスティチュート | 操作されたジスルフィド結合を有する安定化蛋白質 |
| US20080108560A1 (en) | 2002-03-05 | 2008-05-08 | Eli Lilly And Company | Heterologous G-Csf Fusion Proteins |
| US8586538B2 (en) | 2002-04-29 | 2013-11-19 | Stichting Sanquin Bloedvoorziening | Method of treating a patient suffering from a bleeding disorder comprising administering an antibody against the A3-C1 of FVIII |
| TWI312368B (en) | 2002-12-23 | 2009-07-21 | Bristol Myers Squibb Compan | Mammalian cell culture processes for protein production |
| US7041635B2 (en) | 2003-01-28 | 2006-05-09 | In2Gen Co., Ltd. | Factor VIII polypeptide |
| LT1596887T (lt) | 2003-02-26 | 2022-04-25 | Nektar Therapeutics | Polimero-faktoriaus viii fragmento konjugatai |
| EP3002012A1 (en) | 2003-05-06 | 2016-04-06 | Biogen Hemophilia Inc. | Clotting factor-fc chimeric proteins to treat hemophilia |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| ES2371072T3 (es) | 2003-06-12 | 2011-12-27 | Eli Lilly And Company | Proteínas de fusión análogas de glp-1. |
| WO2005063808A1 (en) | 2003-12-31 | 2005-07-14 | Merck Patent Gmbh | Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS |
| US7670595B2 (en) | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
| MX350293B (es) | 2004-11-12 | 2017-09-04 | Bayer Healthcare Llc | Modificacion dirigida al sitio del factor viii. |
| DK1835938T3 (da) | 2004-12-27 | 2013-11-04 | Baxter Int | Polymer-von Willebrand-faktor-konjugater |
| US20110124565A1 (en) | 2005-04-14 | 2011-05-26 | Hans-Peter Hauser | Modified Coagulation Factor VIII With Enhanced Stability and Its Derivatives |
| EP1816201A1 (en) | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
| NZ572050A (en) | 2006-03-31 | 2011-09-30 | Baxter Int | Factor VIII conjugated to polyethylene glycol |
| ES2889920T3 (es) | 2006-06-14 | 2022-01-14 | Csl Behring Gmbh | Proteínas de fusión escindibles proteolíticamente con alta actividad específica molar |
| DK2041270T3 (da) | 2006-07-13 | 2014-01-27 | Wyeth Llc | Fremstilling af glycoproteiner |
| AU2007338298B2 (en) | 2006-12-22 | 2013-02-07 | Csl Behring Gmbh | Modified coagulation factors with prolonged in vivo half-life |
| DK2574677T3 (da) | 2007-12-27 | 2017-11-06 | Baxalta GmbH | Fremgangsmåder til celledyrkning |
| US8575104B2 (en) | 2008-06-24 | 2013-11-05 | Csl Behring Gmbh | Factor VIII, von willebrand factor or complexes thereof with prolonged in vivo half-life |
| KR101808751B1 (ko) | 2009-11-13 | 2017-12-13 | 그리폴스 테라퓨틱스 인코포레이티드 | 폰 빌레브란트 인자(ｖＷＦ)-함유 제제, 및 그와 관련된 방법, 키트 및 용도 |
| PL3330370T3 (pl) | 2010-04-26 | 2021-09-20 | Novartis Ag | Sposób hodowania komórek cho |
| AU2012340501A1 (en) * | 2011-12-19 | 2013-07-11 | Grifols, S.A. | Compositions, methods, and kits for preparing sialylated recombinant proteins |
| MX357403B (es) | 2012-01-12 | 2018-07-09 | Bioverativ Therapeutics Inc | Polipeptidos de factor viii quimericos y usos de los mismos. |
| EP2814502B1 (en) | 2012-02-15 | 2017-09-13 | CSL Behring GmbH | Von willebrand factor variants having improved factor viii binding affinity |
| WO2013083858A1 (en) | 2012-04-24 | 2013-06-13 | Novo Nordisk A/S | Compounds suitable for treatment of haemophilia |
| SE537059C2 (sv) * | 2012-12-21 | 2014-12-23 | Nätstations Alliansen Ab | Elcentral |
| JP2016522219A (ja) * | 2013-06-12 | 2016-07-28 | ノヴォ ノルディスク アー／エス | 血友病の治療に適する化合物 |
-
2016
- 2016-05-20 DK DK16725477.0T patent/DK3298036T3/da active
- 2016-05-20 EP EP16725477.0A patent/EP3298036B1/en active Active
- 2016-05-20 KR KR1020177037165A patent/KR20180012303A/ko not_active Withdrawn
- 2016-05-20 SG SG11201708754XA patent/SG11201708754XA/en unknown
- 2016-05-20 CA CA2986625A patent/CA2986625A1/en active Pending
- 2016-05-20 US US15/576,061 patent/US10772936B2/en active Active
- 2016-05-20 EP EP22160272.5A patent/EP4089109A3/en active Pending
- 2016-05-20 RU RU2017145002A patent/RU2017145002A/ru not_active Application Discontinuation
- 2016-05-20 WO PCT/EP2016/061440 patent/WO2016188905A1/en not_active Ceased
- 2016-05-20 AU AU2016267539A patent/AU2016267539B2/en active Active
- 2016-05-20 BR BR112017024714A patent/BR112017024714A2/pt not_active Application Discontinuation
- 2016-05-20 ES ES16725477T patent/ES2912300T3/es active Active
- 2016-05-20 SG SG10201910900WA patent/SG10201910900WA/en unknown
- 2016-05-20 CN CN201680029616.9A patent/CN107810194B/zh active Active
- 2016-05-20 JP JP2017560681A patent/JP6651548B2/ja active Active
- 2016-05-20 MX MX2017014872A patent/MX2017014872A/es unknown
- 2016-05-23 TW TW105116002A patent/TW201713686A/zh unknown
-
2017
- 2017-11-16 IL IL255711A patent/IL255711A/en unknown
-
2020
- 2020-07-10 US US16/925,411 patent/US10905747B2/en active Active
- 2020-12-29 US US17/136,334 patent/US11564976B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US10905747B2 (en) | 2021-02-02 |
| RU2017145002A (ru) | 2019-06-24 |
| US20180153968A1 (en) | 2018-06-07 |
| AU2016267539B2 (en) | 2019-12-05 |
| SG11201708754XA (en) | 2017-12-28 |
| US20200368327A1 (en) | 2020-11-26 |
| KR20180012303A (ko) | 2018-02-05 |
| BR112017024714A2 (pt) | 2018-09-11 |
| JP2018515125A (ja) | 2018-06-14 |
| CN107810194A (zh) | 2018-03-16 |
| US11564976B2 (en) | 2023-01-31 |
| JP6651548B2 (ja) | 2020-02-19 |
| IL255711A (en) | 2018-04-30 |
| US20210121535A1 (en) | 2021-04-29 |
| EP3298036B1 (en) | 2022-04-06 |
| ES2912300T3 (es) | 2022-05-25 |
| SG10201910900WA (en) | 2020-01-30 |
| EP4089109A3 (en) | 2023-03-01 |
| EP3298036A1 (en) | 2018-03-28 |
| AU2016267539A1 (en) | 2017-11-16 |
| WO2016188905A1 (en) | 2016-12-01 |
| MX2017014872A (es) | 2018-07-06 |
| TW201713686A (en) | 2017-04-16 |
| CN107810194B (zh) | 2021-10-08 |
| HK1250724A1 (zh) | 2019-01-11 |
| CA2986625A1 (en) | 2016-12-01 |
| EP4089109A2 (en) | 2022-11-16 |
| US10772936B2 (en) | 2020-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL261271A (en) | Methods for making l-glufosinate | |
| EP3721827C0 (en) | FIXATION TEMPLATES FOR PLACING DENTAL BRACES | |
| DK3294700T3 (da) | Fremgangsmåde til fremstilling af limonen-4-ol | |
| DK3556775T3 (da) | Anti-lag-3 antistoffer til behandling af hæmatologiske maligniteter | |
| DK3110988T3 (da) | Metoder til behandling af lithiumholdige materialer | |
| DK3122444T3 (da) | Fremgangsmåde til fremstilling af membraner | |
| DK3515990T3 (da) | Fremgangsmåde til fremstilling af lignocellulosematerialer | |
| DK3529233T3 (da) | Fremgangsmåde til fremstilling af 3-alkylsulfanyl-2-chlor-n-(1-alkyl-1h-tetrazol-5-yl)-4-trifluoromethyl-benzamider | |
| DK3166904T3 (da) | Fremgangsmåde til fremstilling af betonelementer | |
| DK3400002T3 (da) | Muteret, trunkeret von willebrand faktor | |
| DK3164150T3 (da) | Modificeret von willebrand-faktor | |
| DK3183237T3 (da) | Fremgangsmåde til fremstilling af 5-fluor-1h-pyrazoler startende ud fra hexafluorpropen | |
| DK3191498T3 (da) | Fremgangsmåde til fremstilling af 2'-o-fucosyllactose | |
| DK3400238T3 (da) | Muteret von willebrand faktor | |
| DK3274143T3 (da) | Fremgangsmåde til fremstilling af lignocellulosematerialer | |
| DK3137449T3 (da) | Fremgangsmåder til fremstilling af substituerede cycloseriner | |
| DK3298036T3 (da) | Fremgangsmåder til forberedelse af modificeret von Willebrand faktor | |
| DK3534709T3 (da) | Substituerede sulfonylamider til bekæmpelse af skadedyr | |
| DK3297656T3 (da) | Trunkeret von Willebrand Faktor polypeptider til behandling af hæmofili | |
| DK3265483T3 (da) | Modificeret von Willebrand-faktor med forbedret halveringstid | |
| DK3408015T3 (da) | Fremgangsmåde til fremstilling af emulsioner | |
| DK3148984T3 (da) | Fremgangsmåde til fremstilling af 5-fluor-1h-pyrazoler startende ud fra hexafluorpropen | |
| DK3265564T3 (da) | Fremgangsmåde til modulering af mecp2-ekspression | |
| EP3467158A4 (en) | Crucible | |
| DK3431590T3 (da) | Fremgangsmåde til fremstilling af aktiveret hepatocytvækstfaktor (hgf) |